ABU DHABI — The United Arab Emirates has activated a new pharmaceutical regulation aimed at reducing medicine prices and preventing supply shortages, in a move expected to benefit millions of residents, particularly expatriates reliant on private healthcare.
On February 24, the Emirates Drug Establishment (EDE) implemented a provision under Federal Decree-Law No. 38 of 2024 requiring pharmaceutical companies to appoint multiple authorised agents for every medicine sold in the country.
The reform effectively ends the long-standing single-distributor model, under which one exclusive agent managed the import, pricing, storage and distribution of each drug.
Industry analysts say the previous system, while administratively streamlined, created vulnerabilities in the supply chain. Manufacturing delays abroad, shipping disruptions or local logistical bottlenecks could result in extended shortages of essential medicines, including insulin, oncology treatments and common antibiotics.
The single-agent structure also limited price competition, keeping costs elevated for many branded medicines and slowing the uptake of generics. This has had a significant impact on expatriate residents, who make up the majority of the UAE’s population and typically rely on private insurance or out-of-pocket payments for treatment.
Under the new framework, multiple agents per product are expected to introduce both redundancy and competition. If one distributor faces delays, others can maintain supply. Companies will also compete on pricing, delivery speed and service agreements with pharmacies and hospitals.
Market observers say liberalisation in comparable markets has led to price reductions of 10 to 20 percent, particularly for chronic disease treatments. In the UAE, where diabetes affects roughly one in five adults and hypertension rates are also high, lower prices could ease pressure on household budgets and insurance co-payments.
The reform is also expected to improve coverage in smaller clinics and in the northern emirates, where supply gaps have been more pronounced.
Major domestic manufacturers are seen as well positioned to expand partnerships and distribution networks under the new rules.
International drugmakers including Pfizer, Novartis, Sanofi, GlaxoSmithKline and AstraZeneca may accelerate local manufacturing, partnerships or clinical research activity to maintain competitiveness in a more open market.
Indian generics manufacturers such as Sun Pharmaceutical Industries and Dr. Reddy’s Laboratories are also expected to explore expanded access.
The UAE pharmaceutical market, currently estimated at between $4 billion and $5 billion, is projected by industry sources to approach $8 billion in the early 2030s, supported by population growth, medical tourism and investment in life sciences.
As a key pharmaceutical hub within the Gulf, the UAE’s regulatory shift may influence policy discussions in neighbouring countries seeking to strengthen supply resilience and local manufacturing under broader economic diversification strategies.
Implementation is expected to take place in phases as companies appoint additional agents and regulators oversee compliance and quality standards. Officials say the objective is to ensure more stable supply, competitive pricing and improved access to medicines while maintaining rigorous safety oversight.
For patients, particularly those managing chronic conditions, the reform signals a shift toward a more competitive and resilient medicines market in one of the region’s fastest-growing healthcare systems.
